Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$113.28 USD

113.28
1,188,830

+0.11 (0.10%)

Updated Sep 16, 2024 04:00 PM ET

After-Market: $113.27 -0.01 (-0.01%) 6:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (160 out of 251)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Here is What to Know Beyond Why Cardinal Health, Inc. (CAH) is a Trending Stock

Cardinal (CAH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The Zacks Analyst Blog Highlights Cardinal Health, The Coca-Cola, General Mills, The Clorox and Cincinnati Financial

Cardinal Health, The Coca-Cola, General Mills, The Clorox and Cincinnati Financial are part of the Zacks top Analyst Blog.

QuidelOrtho's (QDEL) Rapid Antigen Test Gets De Novo FDA Approval

QuidelOrtho's (QDEL) receipt of the FDA's De Novo approval is expected to enable it to provide the test as an aid in the diagnosis of SARS-CoV-2 infections in symptomatic individuals.

Nalak Das headshot

5 Safe Stocks to Buy as SVB Collapse Shakes Wall Street

At this stage, it will be prudent to stay with safe stocks.Five such stocks are: CAH, CINF, CLX, KO and GIS.

After Plunging -10.82% in 4 Weeks, Here's Why the Trend Might Reverse for Cardinal (CAH)

Cardinal (CAH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Cardinal Health (CAH) Stock Moves -0.14%: What You Should Know

Cardinal Health (CAH) closed the most recent trading day at $71.19, moving -0.14% from the previous trading session.

Cardinal Health's (CAH) New Tie-Up to Boost Patient Outcomes

Cardinal Health's (CAH) latest partnership is expected to improve patients' healthcare journey by offering a more integrated experience that connects all sites of care.

3 Reasons Growth Investors Will Love Cardinal (CAH)

Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.

Here's Why You Should Add Stryker (SYK) Stock to Your Portfolio

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on it.

Are Investors Undervaluing Cardinal Health (CAH) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

CVS Health's (CVS) New Acquisitions Aid, Cost Woes Linger

CVS Health (CVS) launches functionality that gives patients more choices and convenience in filling prescriptions.

Is Trending Stock Cardinal Health, Inc. (CAH) a Buy Now?

Cardinal (CAH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

IDEXX (IDXX) Global Sales, Instrument Placement Robust

IDEXX (IDXX) continues to demonstrate solid growth globally, primarily aided by a gain in CAG and Water businesses.

Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Down

Teleflex (TFX) revenues in Asia rise backed by strong contributions from growth in all geographies.

Chemed (CHE) Q4 Earnings Beat Estimates, Margins Contract

Chemed (CHE) reports impressive sales growth in the Roto-Rooter subsidiary in the fourth quarter of 2022.

NuVasive (NUVA) Q4 Earnings Miss Estimates, Margins Down

Inflationary costs, supply chain disruptions, volatility in foreign exchange rates and the persistent COVID-led impact hurt NuVasive's (NUVA) Q4 revenues.

Tandem Diabetes (TNDM) Q4 Earnings Beat, Gross Margin Dips

Tandem Diabetes (TNDM) Q4 GAAP sales reflect an accounting deferral related to the recent introduction of the company's Tandem Choice program in the United States.

Integra Lifesciences (IART) Q4 Earnings Top, Revenues Drop Y/Y

Integra LifeSciences (IART) delivers strong earnings growth in the fourth quarter amid challenging macro environment issues.

Charles River (CRL) Q4 Earnings Top Estimates, Margins Dip

Strength across the DSA and Research Models and Services RMS business segments drove Charles River's (CRL) Q4 revenues.

Exact Sciences (EXAS) Q4 Earnings Top Estimates, Margin Falls

Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences (EXAS) Q4 top line.

Walgreens' (WBA) New Partnerships Aid, Margin Pressure Ails

Walgreens Boots (WBA) raises its U.S. Healthcare target, including fiscal 2025 sales goal.

Globus Medical (GMED) Q4 Earnings Beat, Operating Margin Rises

Globus Medical (GMED) reports strong fourth-quarter sales growth amid currency headwinds and lingering COVID-19 impacts.

Medtronic (MDT) Q3 Earnings Beat Estimates, Margins Down

Medtronic's (MDT) CGM business banks on strong sales of the MiniMed 780G system and the associated increase in CGM attachment rates on the strength of the Guardian 4 sensor in Q3.

Quest Diagnostics (DGX) Base Business Growth Robust, Volume Up

Quest Diagnostics (DGX) starts to benefit from incentives related to these value-based contracts, which help demonstrate the value of these strategic relationships.

Medtronic (MDT) Receives CE Mark Approval For Aurora System

Medtronic (MDT) Aurora EV-ICD system indicated for patients at risk of life-threatening arrhythmias.